Financial Trade Freedom - Investing and Stock News
  • Investing
  • News
  • Editor’s Pick
  • Economy
  • Stock
  • Investing
  • News
  • Editor’s Pick
  • Economy
  • Stock
No Result
View All Result
Financial Trade Freedom - Investing and Stock News
No Result
View All Result
Home Stock

Regeneron stock crashes on COPD data: here’s why I’m buying REGN today

admin by admin
May 30, 2025
in Stock
0
Regeneron stock crashes on COPD data: here’s why I’m buying REGN today
0
SHARES
0
VIEWS
Share on FacebookShare on Twitter

Regeneron Pharmaceuticals Inc (NASDAQ: REGN) crashed more than 15% this morning on disappointing data from Phase 3 trials of its experimental drug itepekimab.

Itepekimab is a drug candidate for chronic obstructive pulmonary disease (COPD) that the biotech firm developed with Paris headquartered Sanofi.

Including today’s plummet, REGN shares are down nearly 35% versus their year-to-date high.

Regeneron stock is going for a huge discount

Despite an unusually difficult first half of 2025, there’s ample reason, including solid fundamentals, to buy Regeneron stock at current levels.  

In 2024, the pharmaceutical behemoth reported $14.2 billion in revenue on $4.4 billion worth of net income, both ahead of consensus.

REGN’s net profit margin stood at just under 27% last year, underscoring its ability to generate substantial earnings from its operations.

From a valuation standpoint, Regeneron shares appear attractive as well.

They’re now going for a price-to-earnings multiple of less than 13 (trailing), well below their historical average and biotech sector median of about 27.

This discount suggests that markets may be undervaluing the company’s earnings potential and growth prospects at the time of writing.

REGN still has exposure to the COPD market

While itepekimab late-stage trials miss the mark, Regeneron flagship product, Dupixent, already has FDA approval for the treatment of COPD, marking its sixth US indication since initial approval for atopic dermatitis.

This suggests that REGN remains well-positioned in the respiratory conditions market even though its itepekimab disappointed on Friday.

Additionally, the biotechnology company spent $256 million earlier this month to buy 23andMe assets, which expand its footprint in genetic research and personalized medicine.

This said acquisition could bolster the company’s drug development pipeline and support long-term growth.

Note that Regeneron stock currently pays a dividend yield of 0.72% as well, which makes it somewhat more attractive to own in 2025.

How analysts recommend playing REGN shares

Investors should also note that analysts remain bullish on Regeneron shares despite the itepekimab setback today.

Citi analysts recently upgraded REGN stock to “buy”, citing stabilising fundamentals and near-term catalysts, including product developments, for instance, fianlimab.

On Friday, analysts at Cantor Fitzgerald also reiterated the biotech stock at “overweight”.

In a note to clients, the investment bank agreed that the disappointing late-stage data could hurt Regeneron for a while but expressed confidence in the firm’s long-term trajectory.

Cantor currently has a $695 price target on Regeneron Pharmaceuticals that indicates potential for a more than 40% upside from current levels.

All in all, while the trial results for itepekimab have introduced short-term volatility, the Nasdaq listed firm’s strong financials, diversified product portfolio, and strategic initiatives position it well for sustained growth moving forward.

Therefore, the company’s current stock price, reflecting a significant discount, offers a potential entry point for investors seeking exposure to a resilient and innovative biotech name.

The post Regeneron stock crashes on COPD data: here’s why I’m buying REGN today appeared first on Invezz


Previous Post

US picks Palantir as data analysis partner, but why you shouldn’t jump into PLTR

Next Post

Why are investors concerned about Marvell’s custom AI chips business?

Next Post
Why are investors concerned about Marvell’s custom AI chips business?

Why are investors concerned about Marvell’s custom AI chips business?

  • Trending
  • Comments
  • Latest
Top 4 catalysts for the Dow Jones and S&P 500 this week

Top 4 catalysts for the Dow Jones and S&P 500 this week

May 25, 2025
U.S. homebuilders raise alarm over tariffs as sentiment falls to 5-month low

U.S. homebuilders raise alarm over tariffs as sentiment falls to 5-month low

February 19, 2025
Denny’s set to close dozens more locations this year, though some openings planned too

Denny’s set to close dozens more locations this year, though some openings planned too

February 16, 2025
KFC moves U.S. headquarters from Kentucky to Texas

KFC moves U.S. headquarters from Kentucky to Texas

February 19, 2025
US stocks could still rally 20% in the second half of 2025: find out more

US stocks could still rally 20% in the second half of 2025: find out more

0
Amazon ‘anti-union propaganda,’ employee surveillance loom over labor vote at North Carolina warehouse

Amazon ‘anti-union propaganda,’ employee surveillance loom over labor vote at North Carolina warehouse

0
As Joann Fabrics and JCPenney announce store closings, here’s what’s driving the pattern

As Joann Fabrics and JCPenney announce store closings, here’s what’s driving the pattern

0
From tariffs to DOGE, what companies are saying about the impact of MAGA policies

From tariffs to DOGE, what companies are saying about the impact of MAGA policies

0
US stocks could still rally 20% in the second half of 2025: find out more

US stocks could still rally 20% in the second half of 2025: find out more

May 31, 2025
Consolidation in the markets

Consolidation in the markets

May 31, 2025
Adobe stock price is cheap: is it a good buy?

Adobe stock price is cheap: is it a good buy?

May 31, 2025
Crypto market today: Cronos price as Dogwifhat, Livepeer plunge

Crypto market today: Cronos price as Dogwifhat, Livepeer plunge

May 31, 2025

    Get Smarter with Your Money – Sign Up for Free Financial Tips!


    Join our community of savvy savers and investors! By signing up, you'll receive weekly emails packed with personalized financial tips, budgeting hacks, and investment strategies tailored to your income level. Take control of your finances today – it’s free and only takes a minute!

    Recent News

    US stocks could still rally 20% in the second half of 2025: find out more

    US stocks could still rally 20% in the second half of 2025: find out more

    May 31, 2025
    Consolidation in the markets

    Consolidation in the markets

    May 31, 2025
    Adobe stock price is cheap: is it a good buy?

    Adobe stock price is cheap: is it a good buy?

    May 31, 2025
    Crypto market today: Cronos price as Dogwifhat, Livepeer plunge

    Crypto market today: Cronos price as Dogwifhat, Livepeer plunge

    May 31, 2025
    • About us
    • Contacts
    • Privacy Policy
    • Terms and Conditions
    • Email Whitelisting
    • About us
    • Contacts
    • Privacy Policy
    • Terms and Conditions
    • Email Whitelisting

    Disclaimer: FinancialTradeFreedom.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

    Copyright © 2025 financialtradefreedom.com | All Rights Reserved

    No Result
    View All Result
    • About us
    • Contacts
    • Email Whitelisting
    • Investing and Stock News
    • Privacy Policy
    • Terms and Conditions
    • Thank you

    Disclaimer: FinancialTradeFreedom.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

    Copyright © 2025 financialtradefreedom.com | All Rights Reserved